The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Avanir Pharmaceuticals's revenues will grow 72.1% and EPS will remain in the red.
The average estimate for revenue is $17.2 million. On the bottom line, the average EPS estimate is -$0.09.
Last quarter, Avanir Pharmaceuticals reported revenue of $16.5 million. GAAP reported sales were much higher than the prior-year quarter's $7.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.09. GAAP EPS were -$0.09 for Q1 against -$0.12 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 94.9%, 80 basis points worse than the prior-year quarter. Operating margin was -66.8%, much better than the prior-year quarter. Net margin was -73.1%, much better than the prior-year quarter.
The full year's average estimate for revenue is $83.5 million. The average EPS estimate is -$0.23.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 184 members out of 245 rating the stock outperform, and 61 members rating it underperform. Among 50 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 36 give Avanir Pharmaceuticals a green thumbs-up, and 14 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Avanir Pharmaceuticals is outperform, with an average price target of $5.50.
- Add Avanir Pharmaceuticals to My Watchlist.